Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TMDX TransMedics Group Inc
- Stocks
- Healthcare
- NASDAQ: TMDX
Price (delayed)
$129.81
Market cap
$4.39B
P/E Ratio
88.31
Dividend/share
N/A
EPS
$1.47
Enterprise value
$4.6B
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need
Highlights
TMDX's P/E is 84% below its last 4 quarters average of 536.3
TMDX's equity has surged by 67% year-on-year and by 16% since the previous quarter
The quick ratio has grown by 12% from the previous quarter but it has contracted by 5% YoY
The gross margin has contracted by 4.6% YoY
Key stats
What are the main financial stats of TMDX
Market
Valuations
Earnings
Shares outstanding
33.83M
Market cap
$4.39B
Enterprise value
$4.6B
Price to earnings (P/E)
88.31
Price to book (P/B)
16.41
Price to sales (P/S)
8.97
EV/EBIT
71.5
EV/EBITDA
52.48
EV/Sales
9.42
Revenue
$488.23M
Gross profit
$290.35M
Operating income
$52.52M
Net income
$48.95M
EBIT
$64.34M
EBITDA
$87.65M
Free cash flow
-$63.23M
Per share
Balance sheet
Liquidity
EPS
$1.47
EPS diluted
$1.37
Free cash flow per share
-$1.87
Book value per share
$7.91
Revenue per share
$14.48
TBVPS
$24.43
Total assets
$837.53M
Total liabilities
$571.22M
Debt
$518.41M
Equity
$266.31M
Working capital
$450.32M
Debt to equity
1.95
Current ratio
9.1
Quick ratio
8.14
Net debt/EBITDA
2.37
Margins
Efficiency
Dividend
EBITDA margin
18%
Gross margin
59.5%
Net margin
10%
Operating margin
10.8%
Return on assets
6.1%
Return on equity
21.9%
Return on invested capital
7.1%
Return on capital employed
8.2%
Return on sales
13.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TMDX stock price
How has the TransMedics Group stock price performed over time
Intraday
0.83%
1 week
0.93%
1 month
44.27%
1 year
-3.47%
YTD
108.2%
QTD
92.94%
Financial performance
How have TransMedics Group's revenue and profit performed over time
Revenue
$488.23M
Gross profit
$290.35M
Operating income
$52.52M
Net income
$48.95M
Gross margin
59.5%
Net margin
10%
The revenue has soared by 64% YoY and by 11% from the previous quarter
TMDX's gross profit has surged by 57% year-on-year and by 11% since the previous quarter
TMDX's operating income is up by 40% QoQ
The net income rose by 38% QoQ
Price vs fundamentals
How does TMDX's price correlate with its fundamentals
Growth
What is TransMedics Group's growth rate over time
Valuation
What is TransMedics Group stock price valuation
P/E
88.31
P/B
16.41
P/S
8.97
EV/EBIT
71.5
EV/EBITDA
52.48
EV/Sales
9.42
TMDX's P/E is 84% below its last 4 quarters average of 536.3
TransMedics Group's EPS has increased by 37% QoQ
TMDX's equity has surged by 67% year-on-year and by 16% since the previous quarter
The stock's P/B is 31% more than its 5-year quarterly average of 12.4 but 5% less than its last 4 quarters average of 17.2
The revenue has soared by 64% YoY and by 11% from the previous quarter
The P/S is 50% lower than the 5-year quarterly average of 17.7 and 2.3% lower than the last 4 quarters average of 9.1
Efficiency
How efficient is TransMedics Group business performance
The ROA is up by 33% since the previous quarter
TransMedics Group's return on equity has increased by 22% QoQ
The ROIC has grown by 22% from the previous quarter
TransMedics Group's return on sales has increased by 16% QoQ
Dividends
What is TMDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TMDX.
Financial health
How did TransMedics Group financials performed over time
The total assets is 47% more than the total liabilities
The total assets has grown by 16% YoY and by 4.2% from the previous quarter
The quick ratio has grown by 12% from the previous quarter but it has contracted by 5% YoY
The company's debt is 95% higher than its equity
TMDX's equity has surged by 67% year-on-year and by 16% since the previous quarter
TMDX's debt to equity is down by 40% year-on-year and by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.